CytomX Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

CytomX Therapeutics

24/03/2023 22:12

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 27. 
    * The South San Francisco California-based  company is
expected to
report  a 9.5% decrease in revenue to $17.847 million from
$19.73 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for CytomX Therapeutics
Inc
is for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $2.73​, above​ its last closing price
of $1.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.29       -0.31      -0.35     Missed  -14.5
 Jun. 30 2022  -0.36       -0.36      -0.37     Missed  -2.8
 Mar. 31 2022  -0.38       -0.36      -0.37     Missed  -1.8​
 Dec. 31 2021  -0.14       -0.28      -0.40     Missed  -41.7
 ​​Sep.        -0.31       -0.31      -0.35     Missed  -12
 30 2021                                                
 Jun. 30 2021  -0.29       -0.32      -0.30     Beat    6​
 Mar. 31 2021  -0.31       -0.35      -0.26     Beat    24.8
 Dec. 31 2020  -0.41       -0.50      -0.32     Beat    36.5
 This summary was machine generated March 24 at 22:12 GMT.  All
figures in US dollars  unless otherwise stated